Results 211 to 220 of about 25,099 (263)
Some of the next articles are maybe not open access.
Cholinesterase Inhibitors and Beyond
Current Alzheimer Research, 2009Cholinesterase inhibitors (ChEIs) were introduced in the therapy of Alzheimer Disease (AD) in the nineteen nineties with great expectations. The hopes and large interest raised by these drugs are well demonstrated by 12,000 references listed by PubMed under 'ChEI' for 1995-2007. The list is reduced to 2500 if we confine ourselves to 'ChEIs and dementia'
PEPEU, GIANCARLO +1 more
openaire +2 more sources
Cholinesterase inhibitors and memory
Chemico-Biological Interactions, 2010A consensus exists that cholinesterase inhibitors (ChEIs) are efficacious for mild to moderate Alzheimer's Disease (AD). Unfortunately, the number of non-responders is large and the therapeutic effect is usually short-lasting. In experimental animals, ChEIs exert three main actions: inhibit cholinesterase (ChE), increase extracellular levels of brain ...
PEPEU, GIANCARLO +1 more
openaire +3 more sources
Journal of Psychiatric Practice, 2003
Dementia is a serious and growing problem that presents enormous burdens to patients, their families, and national healthcare systems throughout the world. In the United States, there are currently two classes of psychopharmacologic agents approved for the treatment of Alzheimer's disease: the cholinesterase inhibitors, which are approved for use in ...
openaire +2 more sources
Dementia is a serious and growing problem that presents enormous burdens to patients, their families, and national healthcare systems throughout the world. In the United States, there are currently two classes of psychopharmacologic agents approved for the treatment of Alzheimer's disease: the cholinesterase inhibitors, which are approved for use in ...
openaire +2 more sources
Cholinesterases and Cholinesterase Inhibitors
Archives of Neurology, 20011. Introduction 2. Cholinesterase Inhibitors: An Introduction 3. Molecular Structure of Cholinesterases and Complexes with Inhibitors 4. Rational Design of Cholinesterase Inhibitors 5. Genetics and Epigenetics of Mammalian Cholinesterases 6. The Gene Structure of Cholinesterases 7. Molecular Forms and Anchoring of Cholinesterases 8. Mechanism of Action
openaire +1 more source
Effect of cholinesterase inhibitors on attention
Chemico-Biological Interactions, 2013Advantages and limits of the use of cholinesterase inhibitors (ChEI) in Alzheimer's disease (AD) are well established. Their effects result from an increase in extracellular acetylcholine (ACh) whose hydrolysis is prevented by cholinesterase inhibition. In this way, the cholinergic deficit which characterizes AD may be corrected.
Giancarlo Pepeu +2 more
openaire +2 more sources
Coumarins as cholinesterase inhibitors: A review
Chemico-Biological Interactions, 2016The first report in literature of the isolation of coumarin was in the year 1820. After this report, other papers were published demonstrating the isolation and synthesis of coumarin and analogues. These compounds have been studying along the years for several different pathologies.
Luana G, de Souza +2 more
openaire +2 more sources
A New Series of Cholinesterase Inhibitors*
Journal of the American Pharmaceutical Association (Scientific ed.), 1954In a series of bis onium biphepyl derivatives, alteration of substitutions on the quaternary nitrogen produced a wide variation in toxicity and ability to inhibit cholinesterase, as well as other pharmacological responses. Three members of this series were found to be equal to neostigmine bromide as inhibitors of bovine erythrocyte cholinesterase ...
J P, LONG, F W, SCHUELER
openaire +2 more sources
Drug Interactions with Cholinesterase Inhibitors
Drugs & Aging, 2003Cholinesterase inhibitors are used for the symptomatic treatment of patients with Alzheimer's disease. This population often has numerous comorbidities and receives treatment with multiple medications. The astute clinician should remain mindful of possible drug interactions, both pharmacokinetic and pharmacodynamic, that may occur with concomitant ...
Jennifer L, Defilippi, M Lynn, Crismon
openaire +2 more sources
Clinical Pharmacokinetics of Cholinesterase Inhibitors
Clinical Pharmacokinetics, 1986This review deals mainly with the pharmacokinetics of the reversible quaternary cholinesterase inhibitors neostigmine, pyridostigmine and edrophonium, which are mainly used to antagonise non-depolarising neuromuscular blockade in general anaesthesia and in the symptomatic treatment of myasthenia gravis.
S M, Aquilonius, P, Hartvig
openaire +2 more sources
Pharmacokinetic studies of cholinesterase inhibitors
Acta Neurologica Scandinavica, 2009The pharmacokinetic of some centrally acting cholinesterase inhibitors that have been used to improve memory in patients with dementia of Alzheimer's type, was compared. The original compound in this class, physostigmine has an elimination half-life of 20-30 min.
M, Johansson, A, Nordberg
openaire +2 more sources